ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer?
作者信息
Miller Phoebe N, Nakakura Eric K
机构信息
Division of Surgical Oncology, Section of Hepatopancreaticobiliary Surgery, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
出版信息
Ann Surg Oncol. 2024 Sep;31(9):6203-6204. doi: 10.1245/s10434-024-15660-8. Epub 2024 Jun 22.
Abstract
摘要
相似文献
1
ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer?ASO作者反思：单纯化疗用于胰腺癌的全新辅助治疗？
Ann Surg Oncol. 2024 Sep;31(9):6203-6204. doi: 10.1245/s10434-024-15660-8. Epub 2024 Jun 22.
2
ASO Author Reflections: Systemic Immune-Inflammation Index (SII) as a Biomarker of Response to Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma.ASO作者反思：全身免疫炎症指数（SII）作为胰腺腺癌患者新辅助治疗反应的生物标志物
Ann Surg Oncol. 2020 Mar;27(3):907-908. doi: 10.1245/s10434-019-08136-7. Epub 2019 Dec 10.
3
ASO Author Reflections: What is the Optimal Method for Predicting a Response to Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Cancer?ASO作者反思：预测胰腺癌新辅助FOLFIRINOX化疗反应的最佳方法是什么？
Ann Surg Oncol. 2024 Feb;31(2):1364-1365. doi: 10.1245/s10434-023-14658-y. Epub 2023 Dec 10.
4
ASO Author Reflections: Neoadjuvant Chemotherapy in cT2N0M0 Gastric Cancer; Time to Revisit Current Recommendations?ASO作者反思：cT2N0M0期胃癌的新辅助化疗；是时候重新审视当前的建议了吗？
Ann Surg Oncol. 2024 Sep;31(9):6038-6039. doi: 10.1245/s10434-024-15688-w. Epub 2024 Jul 4.
5
ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?ASO作者反思：对于局部胰腺导管腺癌（R/BR-PDAC），哪种新辅助化疗方案更好（吉西他滨联合白蛋白结合型紫杉醇对比吉西他滨联合S-1）？
Ann Surg Oncol. 2024 Jul;31(7):4702-4703. doi: 10.1245/s10434-024-15244-6. Epub 2024 May 9.
6
ASO Author Reflections: Is Adjuvant Therapy Necessary for All Patients with Invasive Mucinous Cystic Neoplasms of the Pancreas? Let's De-escalate.ASO作者反思：所有胰腺浸润性黏液性囊性肿瘤患者都需要辅助治疗吗？让我们降低治疗强度。
Ann Surg Oncol. 2024 Nov;31(12):8352-8353. doi: 10.1245/s10434-024-15948-9. Epub 2024 Jul 30.
7
ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer-Resection Cuts the Deal.ASO作者反思：可切除边缘和局部晚期胰腺癌的化疗方案——手术是关键。
Ann Surg Oncol. 2023 Jul;30(7):4429-4430. doi: 10.1245/s10434-023-13484-6. Epub 2023 Apr 19.
8
Perioperative Therapy for Borderline Resectable Pancreatic Cancer: What and When?可切除边缘性胰腺癌的围手术期治疗：是什么以及何时进行？
Ann Surg Oncol. 2019 Jun;26(6):1596-1597. doi: 10.1245/s10434-019-07177-2. Epub 2019 Jan 24.
9
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.局部进展期胰腺癌新辅助治疗中应用立体定向体部放疗和术中放疗联合初始化疗的Ⅱ期临床试验方案
BMC Cancer. 2021 Feb 16;21(1):165. doi: 10.1186/s12885-021-07877-7.
10
Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).对比有或无立体定向体部放射治疗的不同新辅助化疗方案治疗局部进展期胰腺癌的前瞻性随机Ⅱ期临床试验研究方案（BRPCNCC-1）。
Radiat Oncol. 2019 Mar 27;14(1):52. doi: 10.1186/s13014-019-1254-8.
Zotero 插件